Navigation Links
Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
Date:10/20/2011

herapeutics for immuno-inflammatory diseases. In February 2010, Regulus and GlaxoSmithKline entered into a new collaboration to develop and commercialize microRNA therapeutics targeting microRNA-122 for the treatment of hepatitis C infection. In June 2010, Regulus and sanofi-aventis entered into the largest-to-date strategic alliance for the development of microRNA therapeutics with an initial focus on fibrosis. For more information, please visit http://www.regulusrx.com.

Click here to view video segments about microRNA therapeutics and Regulus featuring the company's executives http://www.youtube.com/user/RegulusRx#p/f

Click here to follow Regulus on Twitter at www.twitter.com/regulusrx.

Forward-Looking Statements

This press release includes forward-looking statements regarding the future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus, including statements regarding the therapeutic potential of targeting miR-33a/b. Any statement describing Regulus' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Such forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause the results to differ materially from those expressed or implied by such forward-looking statements. Although these forward-looking state
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
2. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
3. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
4. Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
5. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
6. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
7. Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
8. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
9. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
10. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
11. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... of its Common Stock and Series A Convertible Preferred ... Series A Convertible Preferred Stock is non-voting and convertible ... will be prohibited if, as a result, the holder ... of the Common Stock then outstanding. As part of ...
(Date:9/17/2014)... 17, 2014 A biodegradable polymer ... such as bacteria, fungi, and algae into smaller ... biomass, inorganic compounds, carbon dioxide, and humus in ... base and improved costs, biodegradable polymers are proving ... alternative to conventional polymers. Primary factors that are ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... Mass. , Sept. 17, 2014 ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced that it has been ... and Trademark Office on its unique delivery system ... ) to phagocytic cells for the treatment of ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... 15, 2011 Generex Biotechnology Corporation ( www.generex.com ... the status of the previously announced spinout of ... ). The Company is in the ... several transaction opportunities, including both shell companies and ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... provide an overview of the company,s business strategy at ... the UBS 2011 Global Life Sciences Conference which will ... addition, Geoffrey Nichol, M.B., Ch.B., Sangamo,s executive vice president ...
... Aperion Biologics, Inc. announced that it has reached ... Company,s clinical trial of its Z-Lig™ Anterior Cruciate Ligament ... of the knee. The randomized multicenter study commenced in ... provide safety and performance data in the reconstruction of ...
Cached Biology Technology:Generex Provides Update on Spinout of Antigen Express 2Generex Provides Update on Spinout of Antigen Express 3Generex Provides Update on Spinout of Antigen Express 4Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference 2Aperion Biologics Reaches Midpoint of Enrollment in Z-Lig™ Anterior Cruciate Ligament Reconstruction Medical Device Performance Trial 2
(Date:9/16/2014)... Menopause Society (NAMS) has published its key, evidence-based ... everything from hot flashes to heart disease. The ... for Clinical Care of Midlife Women," was published ... . This is the first, comprehensive set of ... freely available to all clinicians who care for ...
(Date:9/16/2014)... Two Johns Hopkins neuroscientists have discovered the "molecular brakes" ... inner ear cochleas of mice. These "hair cells" translate ... the brain and are interpreted as sounds. If the ... , A summary of the research will be ... Sept. 16. , "The proteins Hey1 and Hey2 act ...
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... world,s top biodiversity hotspot for reptiles and amphibians, according ... from the University of California, Berkeley, Southern Illinois University ... The park, which encompasses lowland Amazonian rain forest, high-altitude ... well known for its huge variety of bird life, ...
... to climate change are being compiled by research groups ... various sources results in different climate projections; hence, the ... arrive at a consensus regarding future climate estimates. ... SIAM Journal on Uncertainty Quantification , authors Matthew ...
... , New Rochelle, NY, February 19, 2014Joseph C. Glorioso, ... devoted much of his research career to developing herpes ... cells. In recognition of his leadership and accomplishments, ... Gene Therapy , a peer-reviewed journal from Mary Ann ...
Cached Biology News:Peru's Manu National Park sets new biodiversity record 2Peru's Manu National Park sets new biodiversity record 3Statistics research could build consensus around climate predictions 2Statistics research could build consensus around climate predictions 3Statistics research could build consensus around climate predictions 4Joseph Glorioso, Ph.D., receives Pioneer Award 2